Notice of allowance for patent application of RCD405 in Canada

Arcede Pharma announces that the patent application for RCD405 has been allowed by a formal notice of allowance from the Canadian Intellectual Property Office.

The patent relates to new molecules with a certain structure that can be used to treat diseases characterized by airway contractions, e.g. COPD, asthma, inflammation and/or vasoconstriction, leading to for example high blood pressure (Canadian patent application No: 3,100,835, NOVEL BRONCHODILATING HETERO-LINKED AMIDES). After formal fees are paid, the patent will be granted, giving Arcede Pharma market exclusivity in Canada through 2039. Patents have previously been granted by the European Patent Office (EPO) and also in Japan and South Africa.

For more information:
Mia Lundblad, CEO
Arcede Pharma AB
mia.lundblad@arcedepharma.com
+46 723 12 27 44

The information was submitted for publication on January 26, 2023.

About Arcede Pharma
Arcede Pharma is aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients. Chronic obstructive pulmonary disease (COPD) is a disease that has a substantial negative impact on patients and causes a lot of suffering. COPD is the third most common cause of death worldwide. For more information: www.arcedepharma.com